ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "juvenile idiopathic arthritis (JIA)"

  • Abstract Number: 974 • 2012 ACR/ARHP Annual Meeting

    Identification of Susceptibility Loci for Inflammatory Arthritis

    K. J. A. Steel1, Anne Hinks2, John Bowes3, Joanna Cobb2, Edward Flynn4, Carl D. Langefeld5, Sampath Prahalad6, Johannes Peter Haas7, John F. Bohnsack8, Stephen Guthery8, Anne Barton1, Susan D. Thompson9 and Wendy Thomson1, 1Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 3Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 4Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, 5Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 6Pediatrics, Emory Children's Center, Atlanta, GA, 7Childrens Hospital, Erlangen, Germany, 8Department of Pediatrics,, University of Utah, Salt Lake City, 9Department of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: One of the principal findings of genome wide association studies in autoimmune diseases has been the substantial overlap of genetic susceptibility loci identified. This…
  • Abstract Number: 2007 • 2012 ACR/ARHP Annual Meeting

    Radiological Peripheral Involvement At Hands, Feet and Hips in Young Adults with Polyarticular Idiopathic Juvenile Arthritis

    Muriel Elhai1, Ramin Bazeli2, Veronique Freire2, Antoine Feydy2, Andre Kahan3, Chantal Job-Deslandre4 and Julien Wipff1, 1Rheumatology A, Paris Descartes University, Cochin Hospital, APHP, Paris, France, 2Radiology B, Paris Descartes University, Cochin Hospital, APHP, Paris, France, 3Service de Rhumatologie A, Rheumatology A, Paris Descartes University, Cochin Hospital, APHP, Paris, France, 4Service de Rhumatologie, Rheumatology A, Paris Descartes University, Cochin Hospital, APHP, Paris, France

    Background/Purpose: Radiographic damage was recently considered to be a feature of poor prognosis in cases of polyarticular juvenile idiopathic arthritis (pJIA). However, most radiographic studies…
  • Abstract Number: 760 • 2012 ACR/ARHP Annual Meeting

    Catch-up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: 2-Year Data From a Phase 3 Clinical Trial

    Fabrizio De Benedetti1, Nicolino Ruperto2, Graciela Espada3, Valeria Gerloni4, Berit Flato5, Gerd Horneff6, Barry L. Myones7, Karen Onel8, James Frane9, Andrew Kenwright10, Terri H. Lipman11, Kamal N. Bharucha9, Alberto Martini7 and D. J. Lovell12, 1Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 2Paediatric Rheumatology International Trials Organisation [PRINTO], Genova, Italy, 3Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genova, Italy, 4Istituto Gaetano Pini, Milan, Italy, 5Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 6Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, 7Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, 8PRCSG, Cincinnati, OH, 9Genentech, South San Francisco, CA, 10Roche, Welwyn Garden City, United Kingdom, 11University of Pennsylvania School of Nursing, Philadelphia, PA, 12Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA), characterized by chronic arthritis associated with prominent systemic and laboratory features, also has a significant impact on the growing…
  • Abstract Number: 2011 • 2012 ACR/ARHP Annual Meeting

    ACR Criteria, Providers’ Global Rating of Change and Role of Patient Self-Report in Evaluating Change in Disease Over Time: A Patient Reported Outcomes Measurement Information System Study

    Bin Huang1, Jennifer Farrell2, Adam Carle3, Stacey Niehaus3, Hermine Brunner4, Alexei A. Grom5, Michael Henrickson6, Jennifer L. Huggins4, D. J. Lovell7, Tracy V. Ting4 and Esi M. Morgan DeWitt2, 1Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, 2Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5PRCSG, Cincinnati, OH, 6MLC 4010, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: As part of a longitudinal study of Juvenile Idiopathic Arthritis (JIA), providers completed clinical outcomes assessments and patients (pt) completed self-report measures at clinic…
  • Abstract Number: 762 • 2012 ACR/ARHP Annual Meeting

    Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis

    Yukiko Kimura1, Jennifer E. Weiss2, Kathryn L. Haroldson1, Tzielan C. Lee3, Marilynn G. Punaro4, Sheila K. Feitosa de Oliveira5, C. Egla Rabinovich6, Meredith P. Riebschleger7, Jordi Anton8, Peter R. Blier9, Valeria Gerloni10, Melissa M. Hazen11, Elizabeth Kessler12, Karen Onel13, Murray H. Passo14, Robert M. Rennebohm15, Carol A. Wallace16, Patricia Woo17, Nico M. Wulffraat18 and CARRAnet Investigators19, 1Pediatric Rheumatology, JM Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, 2Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, 3Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, 4Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, 5Pediatric Rheumatology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 6Pediatric Rheumatology, Duke University Medical Center, Durham, NC, 7Pediatric Rheumatology & Health Services Research, University of Michigan, Ann Arbor, MI, 8Rheumatology, Hospital Sant Joan de Deu, Barcelona, Spain, 9Pediatrics, Baystate Children's Hospital, Springfield, MA, 10Pediatric Rheumatology, Gaetano Pini Chair of Rheum, Milan, Italy, 11Division of Immunology, Boston Children's Hospital, Boston, MA, 12Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, 13Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, 14Pediatrics, Medical University of South Carolina, Charleston, SC, 15Pediatric Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, 16Pediatrics, Seattle Childrens Hospital, Seattle, WA, 17Division of Infection and Immunity, University College London, London, United Kingdom, 18Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 19Durham

    Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is characterized by fevers, rash and arthritis, for which IL1 and IL6 inhibitors appear to be effective.  Pulmonary artery…
  • Abstract Number: 2018 • 2012 ACR/ARHP Annual Meeting

    Juvenile Idiopathic Arthritis in Adulthood: Evaluation of Disease Activity, Damage and Quality of Life

    Alessandra Salmaso1, Lorenzo Ceri2, Serena Capannini2, Francesco La Torre3, Maurizio Gattinara4, Irene Pontikaki1, Pier Luigi Meroni5, Fernanda Falcini2 and Valeria Gerloni1, 1Pediatric Rheumatology, G. Pini Institute, Department and Chair of Rheumatology, Milan, Italy, 2Department of Internal Medicine, Rheumatology Section, Transition Clinic, University of Florence, Firenze, Italy, 3DIMIMP-University, Rheumatologic Section, Bari, Italy, 4Pediatric Rheumatology, Pediatric Rheumatology, G. Pini Institute, Department and Chair of Rheumatology, Milan, Italy, 5Dept. of clinical and community science, Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy

    Background/Purpose: : Health outcomes in Juvenile Idiopathic Arthritis (JIA) have been a very active area of research in the past several years. Altogether, the available…
  • Abstract Number: 475 • 2012 ACR/ARHP Annual Meeting

    Immunologic Responsiveness in Patients with Juvenile Idiopathic Arthritis On Methotrexate and Etanercept: 23 Valent Pneumococcal Vaccination

    Ankur A. Kamdar1, Patricia C. Giclas2 and Barry L. Myones3, 1Rheumatology, University of Texas Medical School at Houston, Houston, TX, 2Pediatric Allergy and Immunology, National Jewish Health, Denver, CO, 3Pediatrics, Baylor College of Medicine, Houston, TX

    Background/Purpose: There is a paucity of data regarding response to vaccinations in patients with juvenile idiopathic arthritis (JIA) treated with methotrexate (MTX). It is also…
  • Abstract Number: 2019 • 2012 ACR/ARHP Annual Meeting

    A Novel MRI Scoring System for the Evaluation of Early-Stage Disease Activity of the Wrist in Juvenile Idiopathic Arthritis

    Charlotte M. Nusman1, Robert Hemke1, Taco W. Kuijpers2, Eline E. Deurloo1, Dieneke Schonenberg3, J. Merlijn Van den Berg4, Koert M. Dolman5, Marion A.J. Van Rossum4 and Mario Maas1, 1Department of Radiology, Academic Medical Center, Amsterdam, Netherlands, 2Pediatric Rheumatology and Immunology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands, 3Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, 4Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center and Reade Institute, Amsterdam, Netherlands, 5Pediatric Rheumatology, St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands

    Background/Purpose: Evidence that early therapeutic intervention prevents structural damage in juvenile idiopathic arthritis (JIA) patients requires focus on early-stage disease activity scores. Most outcome measures…
  • Abstract Number: 339 • 2012 ACR/ARHP Annual Meeting

    Differences Between Juvenile and Adult Rodents with Collagen Induced Arthritis

    Tracy D. Wilson-Gerwing1, Isaac V. Pratt2, David M.L. Cooper2, Tawni I. Silver3 and Alan M. Rosenberg4, 1Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, 2Anatomy and Cell Biology, University of Saskatchewan, Saskatoon, SK, Canada, 3Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada, 4Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is among the most common chronic diseases of childhood.  Arthritis is a potentially disabling disease that can result in ongoing…
  • Abstract Number: 1837 • 2012 ACR/ARHP Annual Meeting

    Which Rheumatoid Arthritis, Ankylosing Spondylitis and Juvenile Idiopathic Arthritis Patients Initiate Anti-TNFá Therapy?

    Alain Saraux1, Jacques Benichou2, Chantal Deslandre3, Loic Guillevin4, Latifa Idbrik5, Jean Sibilia6, Marc Soudan5, Daniel Wendling7 and Francis Guillemin8, 1Rheumatology, CHU de la Cavale Blanche and Université Bretagne occidentale, Brest Cedex, France, 2INSERM U657 Pharmacoepidemiology and evaluation of the impact of health products on human health, France, and Department of Biostatistics, University Hospital of Rouen, Rouen, France, EA4438 Laboratoire Physiopathologie des Arthrites, Rouen, France, 3Rheumatology, Cochin Hospital, Paris, France, 4Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, 5Ecole de Sante Publique, Faculte de Medecin/BP 184, Vandoeuvre-les-Nancy, France, 6Université de Strasbourg, EA4438 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, 7Service de Rhumatologie, Minjoz University Hospital, Besancon, France, 8Hopitaux de Brabois, Nancy, France

    Background/Purpose: Comprehensive guidelines for anti-TNFα were proposed in 2005 by the French Society for Rheumatology (SFR) in France; they did not include any economic considerations…
  • Abstract Number: 317 • 2012 ACR/ARHP Annual Meeting

    Fatty Acid Profiling: Potential New Biomarkers in Juvenile Idiopathic Arthritis (pilot study)

    Weng Tarng Cham1, Enzo Ranieri2, Janice Fletcher2 and Christina A. Boros3, 1Paediatric Rheumatology, Women's and Children's Hospital, North Adelaide, SA 5006, Australia, 2Chemical Pathology and Molecular Genetics, SA Pathology, North Adelaide, SA 5006, Australia, 3Paediatrics, University of Adelaide/Women's and Children's Hospital, Adelaide, Australia

    Background/Purpose: The prostanoids are a family of biologically active lipids derived from the 20-carbon essential fatty acids (LCPUFA) all of which are involved in the…
  • Abstract Number: 1644 • 2012 ACR/ARHP Annual Meeting

    Enhanced Pharmacovigilance Reporting of Malignancies in Children and Young Adults Taking Etanercept

    Michele Hooper1, Deborah Wenkert2, Bojena Bitman3, Virgil C. Dias4, Yessinia Bartley5, Julie Wang6 and Julia R. Gage7, 1Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, 2Inflammation TA, Amgen Inc., Thousand Oaks, CA, 3Amgen, Inc., San Francisco, CA, 4Amgen Inc., Thousand Oaks, CA, 5Assent Consulting, Solana Beach, CA, 6Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA, 7Gage Medical Writing, LLC, Oak Park, CA

    Background/Purpose: Recent reports suggest an increased rate of malignancy in children with juvenile idiopathic arthritis (JIA) (Simard, A&R 2010;62:3776; Beukelman A&R 2012;64:1263).  In 2011, the…
  • Abstract Number: 321 • 2012 ACR/ARHP Annual Meeting

    Glycosylation of Vitamin D Binding Protein Reduced in Juvenile Idiopathic Arthritis Patients At Risk of Disease Extension

    David S. Gibson1, Sorcha Finnegan2, Gwen Manning3, Mark Duncan4, Stephen R. Pennington5, Terry L. Moore6 and Madeleine Rooney7, 1Centre for Infection and immunity, Arthritis Research Group, Queens University Belfast, Belfast, United Kingdom, 2Centre for Infection and Immunity, Queen's University, Belfast, Belfast, United Kingdom, 3Proteome Research Centre, University College Dublin, Dublin, Ireland, 4Division of Endocrinology, University of Colorado, Denver, 5UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland, 6Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO, 7Medicine, Queens University Belfast, Belfast, United Kingdom

    Background/Purpose: Juvenile idiopathic arthritis (JIA) comprises a poorly understood group of chronic, childhood onset, autoimmune diseases with variable clinical outcomes.We investigated whether profiling of the…
  • Abstract Number: 1597 • 2012 ACR/ARHP Annual Meeting

    Efficacy and Safety of Tocilizumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Data From a Phase 3 Trial

    Hermine Brunner1, Nicolino Ruperto2, Zbigniew Zuber3, Caroline Keane4, Olivier Harari5, Andrew Kenwright4, Rubén J. Cuttica6, Vladimir Keltsev7, Ricardo Xavier3, Inmaculada Calvo Penades7, Irina Nikishina8, Nadina Rubio-Perez9, Ekaterina Alekseeva10, Vyacheslav Chasnyk11, Jose Chavez3, Gerd Horneff12, Violetta Opoka-Winiarska3, Pierre Quartier13, Clovis A. Silva7, Earl D. Silverman14, Alberto Spindler14, D. J. Lovell15, Alberto Martini14 and Fabrizio De Benedetti16, 1Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Paediatric Rheumatology International Trials Organisation [PRINTO], Genova, Italy, 3PRINTO, Genoa, Italy, 4Roche, Welwyn Garden City, United Kingdom, 5Roche Products Ltd., Welwyn Garden City, United Kingdom, 6Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, 7Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genoa, Italy, 8Pediatric Department, Scientific Research Institute of Rheumatology RAMS, Moskow, Moskow, Russia, 9Hospital Universitario Dr. José Eleuterio Gonzalez, Monterrey, Mexico, 10Istituto Giannina Gaslini, Genoa, Italy, 11Hospital Pediatry, State Pediatric Medical University, Saint-Petersburg, Russia, 12Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, 13Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, 14Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, 15Cincinnati Children's Hospital, Cincinnati, OH, 16PRINTO and PRSCG, Genoa, Italy

    Background/Purpose: Elevated IL-6 levels are associated with disease activity in patients (pts) with juvenile idiopathic arthritis (JIA).1 Tocilizumab (TCZ), an IL-6 receptor inhibitor, was evaluated…
  • Abstract Number: 123 • 2012 ACR/ARHP Annual Meeting

    Detection of Synovitis in Clinically Inactive Juvenile Idiopathic Arthritis Patients by Ultrasonography with POWER Doppler

    Paz Collado1, MariLuz Gamir2, Rosa Merino3, Consuelo Modesto4, Indalecio Monteagudo5 and Juan Carlos Lopez-Robledillo6, 1Rheumatology, Severo Ochoa University Hospital, Madrid, Spain, 2Rheumatology, Ramon y Cajal University Hospital, Madrid, Spain, 3Hospital Universitario La Paz, Madrid, Spain, 4Hospital Valle de Hebron, Barcelona, Spain, 5Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, 6Hospital Niño Jesus, Madrid, Spain

    Background/Purpose: The advances in therapeutic effectiveness have created a need for looking for imaging tools that describe more precisely the clinical state of disease inactivity.…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology